Trevi Therapeutics (TRVI) Enterprise Value (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Enterprise Value of -$171.8 million for Q1 2026, down 66.36% year-over-year from -$510.7 million in Q1 2025, and up 8.75% quarter-over-quarter from -$188.3 million in Q4 2025.
Trevi Therapeutics (TRVI) Enterprise Value (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Enterprise Value history runs 9 years deep, the most recent figure standing at -$171.8 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 66.36% year-over-year to -$171.8 million; the TTM figure through Mar 2026 stood at -$171.8 million (down 66.36% YoY), while the FY2025 annual figure was -$188.3 million, down 74.93% from the prior year.
- Enterprise Value for Q1 2026 stood at -$171.8 million, up from -$188.3 million in the prior quarter.
- The five-year high for Enterprise Value was -$42.3 million in Q1 2022, with the low at -$203.9 million in Q2 2025.
- The 5-year median for Enterprise Value is -$103.3 million (2025), against an average of -$113.0 million.
- The sharpest annual moves came in 2022 and 2024: Enterprise Value sank 328.42% in 2022, then soared 34.55% in 2024.
- Trevi Therapeutics' Enterprise Value stood at -$120.5 million in 2022, then jumped by 31.15% to -$83.0 million in 2023, then declined by 29.71% to -$107.6 million in 2024, then tumbled by 74.93% to -$188.3 million in 2025, then climbed by 8.75% to -$171.8 million in 2026.
- Business Quant data shows TRVI's Enterprise Value at -$171.8 million in Q1 2026, -$188.3 million in Q4 2025, and -$194.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | -318.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -318.87 Mn |
| Mar 31, 2026 | -171.78 Mn |
| Dec 31, 2025 | -188.26 Mn |
| Sep 30, 2025 | -194.93 Mn |
| Jun 30, 2025 | -203.89 Mn |
| Mar 31, 2025 | -103.26 Mn |
| Dec 31, 2024 | -107.62 Mn |
| Sep 30, 2024 | -65.49 Mn |
| Jun 30, 2024 | -69.50 Mn |
| Mar 31, 2024 | -72.82 Mn |
| Dec 31, 2023 | -82.97 Mn |
| Sep 30, 2023 | -88.87 Mn |
| Jun 30, 2023 | -94.15 Mn |
| Mar 31, 2023 | -111.26 Mn |
| Dec 31, 2022 | -120.51 Mn |
| Sep 30, 2022 | -125.60 Mn |
| Jun 30, 2022 | -77.86 Mn |
| Mar 31, 2022 | -42.33 Mn |
| Dec 31, 2021 | -36.83 Mn |
| Sep 30, 2021 | -29.32 Mn |